EASD

EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

ASSOCIATION EUROPEENNE POUR L'ETUDE DU DIABETE · EUROPÄISCHE GESELLSCHAFT FÜR DIABETOLOGIE

Rheindorfer Weg 3 · D-40591 Düsseldorf · Germany · Tel: +49-211-7 58 46 90 · Fax: +49-211-75 84 69 29

E-mail: secretariat@easd.org · Homepage: <http://www.easd.org>

EASD

News Section

9/2004

Welcome to new Members of the EASD

Executive Committee:

President:
Prof. Ele Ferrannini
University of Pisa
Department of Internal
Medicine
Via Roma 67
I-56126 Pisa
Italy

Honorary Secretary:
Prof. Decio L. Eizirik
Director,
Laboratory of
Experimental Medicine
Free University
Brussels (ULB)
808 Route de Lennik,
CP 618
B-1070 Brussels
Belgium

New Members of the EASD Council:

Dr. Leszek Czupryniak
Medical University
of Lodz
Metabolic Disorders
and Gastroenterology
Department
Kopcinskiego 22
PL-90 153 Lodz
Poland

Prof. Luis Gardete
Correia
APDP Associação
Protectora do
Diabéticos de Portugal
Instituição Particular
de Solidariedade
Social
R. Salitre, 118 – 120
P-1250-203 Lisbon
Portugal

Dr. Didac Mauricio
Unit of Endocrinology
Hospital de Sabadell
Parc Tauli S/N
E-08208 Sabadell
Spain

Dr Timo Otonkoski
Biomedicum Helsinki
Program of
Developmental &
Reproductive Biology
Room c530b,
PO Box 63
Haartmaninkatu 8
FIN- 00014
University Helsinki
Finland

EASD Young Scientists Training Course 2005

– Supported by Eli Lilly –

EASD will hold its **Twelfth Young Scientists Training Course in Bristol, UK from 21 to 26 June 2005**.

By organising the Scientists Training Course, EASD hopes to attract new talent to diabetic research, in addition to fostering diabetes research in new centres throughout the world. The Selection Committee (Chair: D. Geremia Bolli; co-Chair: Dr. Claes Hellerström) will be looking for candidates under the age of 40 with some experience in research and who work in an academic environment. A letter of support from the head of the academic department will be considered an essential part of the application. The Course will be held in English and it is understood that all applicants will be able to communicate in this language. All participants will be required to attend the entire Course.

Venue and organisers

The twelfth Course will be hosted by the University of Bristol, U.K. (www.bris.ac.uk) and organised by Professor Guy A Rutter and colleagues.

Format

A hands-on practical course will be provided for a maximum of 16 participants, who will rotate in groups through the laboratories. Each day will begin with an overview of the day's schedule followed by thematic blocks, which will consist of brief introductory lectures and practical training sessions. A discussion on the day's topics will conclude each day.

Focus

This course is designed to provide hands-on training in some of the basic aspects of islet biology including islet isolation, insulin secretion and mRNA extraction, as well as higher level instruction on calcium and ATP imaging, quantitative RT PCR, apoptosis assessment and oligonucleotide microarrays. There will also be lectures on other aspects of islet biology and diabetes. The modular concept of sessions will provide for intensive interaction with trainers and trainees. Overall the principal goal of this course is to provide detailed knowledge and skills in various methods, so that the participants should be able to set up those techniques at their home institutions.

Techniques

Islet isolation, culture and infection with adeno- and retroviruses

Insulin secretion *in vitro* (radioimmunoassay)

Islet and single cell imaging: calcium (fluorescent probes), vesicle movement (confocal and total internal reflection fluorescence microscopy using targeted GFPs and other probes), ATP (recombinant targeted luciferases; ultra-low light level imaging), NAD(P)H (confocal)

RNA isolation; purification; RT-PCR; Microarray analysis

Criteria and eligibility for acceptance to the Course

Any member of EASD who is still under the age of 40 on 1 June 2005 is eligible. The number of participants is strictly limited and the most suitable candidates will be selected by the sub-committee on the basis of the information provided in the application form.

Cost of the Course

Applicants will be asked to pay Euro 240 registration fee, as well as their transportation to and from Bristol, UK. All other expenses, including board and lodging, will be covered by EASD funds, supported by Eli Lilly. Each applicant will be evaluated for eligibility and following individual requests, the registration fee may be waived. In exceptional circumstances and following a formal application, EASD may, if necessary, also provide a travel grant.

Application procedures

Interested candidates should submit their application as a Word file attachment to secretariat@easd.org or by post (4 copies) to:

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

The application must include the following:

- I. A curriculum vitae giving date and place of birth, current professional address (with telephone and fax numbers and email address) and full details of

education and academic and/or clinical career to date. There should be a complete list of publications and mention of any meetings or workshops attended.

- II. A one-page letter of support from the Head of the applicant's current Department. Aside from attesting to the qualities of the candidate, this letter should clearly state how the department proposes to provide the necessary facilities and support to allow the candidate to continue in diabetes research.

- III. A one-page description of the applicant's current research interests, including a brief explanation of how the applicant feels the Course will help in a future career in diabetes research.

Applications not including these pages will not be considered.

Applications must be received at the EASD Secretariat in Düsseldorf before 14 January 2005 (regardless of postmark).

Report of the 9th Spring Scientific Meeting of the EASD PsychoSocial Aspects of Diabetes (PSAD) Study Group

Amsterdam, The Netherlands, 23–25 April 2004

The 9th Spring Scientific Meeting of the PsychoSocial Aspects of Diabetes (PSAD) Study Group of the European Association for the Study of Diabetes (EASD) took place in Amsterdam this year, hosted by Professor Frank Snoek, the PSAD Chair.

Thirty-six delegates (including 10 new members) attended from 13 countries (Belgium, Croatia, Denmark, Germany, Italy, The Netherlands, Romania, Russia, Slovenia, Sweden, Greece, UK and USA). At the business meeting Professor Frank Snoek (The Netherlands) announced that PSAD will hold a diabetes symposium during the International Conference for Behavioural Medicine (ICBM) in Mainz, Germany (25–28 August 2004), and will convene an official symposium with the Diabetes Education Study Group at the EASD in Munich, Germany (5–9 September 2004).

The theme of this year's meeting was the psychological impact of diabetes complications and it was with great pleasure that Dr Snoek invited Professor Andrew Boulton (UK), Consultant Diabetologist and the Honorary Secretary of EASD, to deliver the Anita Carlson Lecture, entitled: "The challenge of the long-term complications of diabetes". The focus of Professor Boulton's talk was on end-stage renal disease. He described the onerous treatment options and how overwhelming these can be in terms of the proportion of each day that can be taken up with treatment. He also stressed the importance of education and training (for both patients and the nurses who care for them), before moving on to discuss the psychological effects of peripheral neuropathy. Given that hyperglycaemia can remain undetected for many years before diabetes is diagnosed (often through the presence of one or more complications), Professor Boulton asked how we can raise awareness of complications without raising anxiety levels.

The following morning commenced with oral presentations of 'work in progress' (otherwise known as

projects being planned or newly started), chaired by Dr Bob Anderson (USA). Dr Christel Hendrieckx (Belgium) started the session by presenting her exciting work on the psychological impact of islet cell transplantation. Dr Hendrieckx showed that at 12 month follow-up people who had undergone islet cell transplantation had improved metabolic control but had increased levels of anxiety. This may have been related to concerns about treatment, side-effects of medication and uncertainty of outcome. Bart Thoolen (The Netherlands) then presented his thought-provoking work on a behavioural intervention designed to help self-management. This was part of the well-known ADDITION study in which three countries (UK, Denmark and The Netherlands) are currently participating.

Dr Arie Nouwen (UK) concluded this session by outlining his plans for a novel study of emotional reactions to food-related cues in people with Type 2 diabetes.

The second session of the morning, chaired by Dr Chas Skinner (UK), continued the theme of 'work in progress'. First, Koula Asimakopoulou (UK) talked about her research on the perceptions of risk of the development of diabetes complications, in particular for coronary heart disease and stroke. Then Dr Bernard Kulzer (Germany) discussed a research project on possible ways of implementing Type 2 diabetes prevention into clinical practice. Dr Kulzer emphasised the importance of combining weight reduction and physical activity in the one intervention as well as focussing on empowerment and self-management abilities of the participants.

In the final session of the morning, the Vice Chairman of PSAD, Dr Norbert Hermanns (Germany), presented the 1st PSAD/Novo Nordisk Science Award to Dr Frans Pouwer (The Netherlands). This peer-

reviewed award was set up to stimulate and reward excellence in psychosocial research in diabetes. Dr Pouwer gave a presentation of his work on how structured monitoring of well-being is able to improve the psychological well-being of people with diabetes. His award-winning paper has now been published in *Diabetes Care*, 2001;24:1929–1935.

Following lunch, Dr Mirjana Pibernik (Croatia) chaired a session of “completed work”, starting with a presentation by Dr Frank Petrak (Germany) on coping with Type 1 diabetes during the first two years after diagnosis. This interesting work demonstrated that coping strategies change over time and may be associated with stage of the disease. Dr Rachel Povey (UK) then gave an illuminating talk on dietary self-care in people with Type 2 diabetes. She showed the importance of understanding people’s underlying beliefs if we are to encourage appropriate and effective dietary self-care. Finally in this session Dr Mark Peyrot (USA) presented his research on the relationship between complications and psychological well-being, using data from the DAWN (Diabetes Attitudes, Wishes and Needs) Study. Dr Peyrot’s fascinating analysis suggested that the experience of diabetes complications increases people’s concerns about negative health and social consequences, which in turn contribute to poor psychological well-being. These data have clear implications for diabetes care and the potential for psychosocial interventions to improve psychological well-being.

The afternoon concluded with a poster presentation session, in which 7 members exhibited their research. Dr Frans Pouwer (The Netherlands) presented a review of the literature on the role of long-chain omega-3 polyunsaturated fatty acids in the prevention and/or treatment of depression. Anke Braun (Germany) presented the results of a trial of a structured treatment and teaching programme for older people with Type 2 diabetes. She demonstrated that participation in a programme such as this can improve quality of life and reduce fear of hypoglycaemia. Another interesting poster was that by Dr Nuha Saleh-Stattin (Sweden), who reported on the development of a diabetes education programme for immigrant patients with diabetes. Dr Hilary Hearnshaw (UK) presented her plans for an exploratory study to record and analyse the insights and experiences of people who have lived with Type 1 diabetes for more than two decades, with the aim to understand the role of psychosocial factors in the development of or absence of diabetes complications. Alette Wessels (The Netherlands) described plans for an innovative piece of research to examine the effect of microvascular disease on the ability of the cerebral circulation to respond with an adequately increased blood flow following acute hypoglycaemia. A second hypothesis to be examined is that impaired acute microvascular response to hypoglycaemia will adversely affect performance in a memory task. Dr Maria

Colombini also presented some work in progress, which is aimed at increasing the understanding of the implications of diabetes in adolescents’ day-to-day lives. A further objective of Dr Colombini’s research is to improve awareness of the need for clear information for appropriate self-management in these young people. Finally, Mirela Pop presented practical strategies for overcoming psychological insulin resistance. This is a common problem found in many different countries represented at PSAD.

For the social programme on Saturday evening, delegates and their guests enjoyed a canal boat tour of Amsterdam, followed by a superb dinner (during which the waiters and waitresses provided excellent musical entertainment).

On Sunday morning, the final session of the PSAD meeting (oral presentations of “completed work”) was chaired by Dr Karin Kanc (Slovenia). Dr Arie Nouwen (UK) began the session with a presentation on the motivational determinants of dietary self-care. In an interesting study of French-Canadian adults with diabetes, Dr Nouwen demonstrated that self-efficacy and autonomous self-regulation predicted changes in self-care only in those people who were highly autonomous. Dr Elena Surkova (Russia) then presented her research on diabetes and depression, in particular the reaction to the diagnosis of diabetes complications. Dr Surkova suggested that there was a brief depressive reaction to complications, which could be considered similar to an adjustment disorder. The final presentation was given by Dr Marie Clark (UK), and led to an interesting debate on lifestyle behaviour change in people with Type 2 diabetes.

The 9th annual meeting saw Professor Frank Snoek (the Netherlands), the founder of PSAD, stepping down from his role as Chairperson. To mark this occasion, the incoming Chair, Dr Norbert Hermanns (Germany), gave a very well-received presentation to honour Professor Snoek. Using a well-constructed and highly amusing metaphor of the PSAD as a child that we have nurtured from infancy to adulthood, Dr Hermanns described the development of the PSAD under the leadership of Professor Snoek over the past 9 years, from the small fledgling group of researchers to internationally renowned group. It was a proud and emotional time for all as Professor Snoek received a standing ovation from the delegates. Dr Cathy Lloyd (UK) then thanked Dr Nuha Saleh-Stattin (Sweden) on behalf of the PSAD members for her incredibly hard work over the years as Honorary Secretary. Further thanks were given to Dr Jane Speight (UK) as outgoing Honorary Treasurer of the PSAD, by Dr Mirjana Pibernik (Croatia), who will be the new Treasurer. It remained for the new Chair of PSAD, Dr Norbert Hermanns to thank our sponsors, Soren Skovlund and Lisbeth Vang (Novo Nordisk, Denmark) for their excellent organisation of the meeting, their generous sponsorship and their hospitality, be-

fore declaring this exciting, thought-provoking meeting closed.

The PSAD provides an excellent forum for presentations by experienced and more junior researchers alike. The abstract deadline for our next Spring Scientific Meeting, to be held in Germany, 22-24 April 2005 will be later this year. New members are welcome to apply for membership at that time. For further information, go to the PSAD website (www.emgo.nl/psad) or contact the Honorary Secretary:

Cathy Lloyd, PhD
The Open University
School of Health & Social Welfare
Walton Hall
Milton Keynes, MK7 6AA
UK
E-mail: C.E.Lloyd@open.ac.uk

Travel grants are awarded each year to junior members and those from Eastern European countries on a competitive basis. Applications are made at the time of submission of abstracts (date to be announced). The PSAD Novo Nordisk Research Award (details available from the Honorary Secretary) will be awarded to the sole or main author of an outstanding peer-reviewed paper furthering our understanding of the psychosocial aspects of diabetes.

Cathy E. Lloyd Ph.D.
Honorary Secretary of the PSAD

Announcement of the Beta-Cell Gene Expression Bank

We are presently constructing an open and user-friendly database aiming to include all genes expressed in pancreatic beta-cells, the "Beta-Cell Gene Expression Bank". This project is developed as a collaboration between the Laboratory of Experimental Medicine, ULB, Belgium (contact person: Prof. D.L. Eizirik) and the JDRF Center for Bioinformatics at the Institute for Systems Biology (ISB) (contact person Dr Nathan Goodman) with support from the JDRF. The first 4,500 beta cell genes have been deposited and more than 200 of these genes are already functionally annotated. The Beta Cell Gene Expression is accessible at http://t1dbase.org/cgi-bin/enter_bcgb.cgi.

This Bank currently runs with 2 approaches: 1) a Fast-track in which we show beta-cell gene expression expressed either under basal condition or following exposure to agents that contribute to beta-cell death in T1DM, as detected by our microarray analysis; 2) a Manually and Functionally Annotated Set in which expert beta-cell researchers at the Laboratory

of Experimental Medicine annotate all cytokine- and virally- induced beta-cell genes. Annotation focuses on putative functions and the role of the gene under study for beta-cell dysfunction and death. This annotated set will eventually include all rat, mouse and human beta-cell genes included in the fast track. The annotated genes will be linked to schematic presentations of functional clusters or pathways utilizing novel software available at the Type 1 diabetes database at the Institute of Systems Biology (ISB). Key transcription factors regulating these clusters will be identified.

In conclusion, this cumulative information, well organized and accessible to the scientific community, will save enormous amounts of time for scientists studying global beta-cell gene expression in T1DM or islet transplantation. Moreover, it will be instrumental for a better understanding of the process of beta-cell death and for the development of new approaches to prevent it.

European Foundation for the Study of Diabetes

The Research Foundation of the European Association for the Study of Diabetes

Request for Applications (RFA)

European Foundation for the Study of Diabetes (EFSD)

and

Novo Nordisk

CONTINUING PROGRAMME OF SUPPORT FOR EUROPEAN DIABETES RESEARCH

ANNOUNCING UP TO EURO 2.1 MILLION IN ADDITIONAL FUNDS FOR DIABETES RESEARCH IN EUROPE

Background

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the *European Foundation for the Study of Diabetes (EFSD)*. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

Plan and Research Focus

The EFSD / Novo Nordisk Programme in diabetes research will accept applications within any area of basic or clinical diabetes research. Those focusing on psycho-social aspects of diabetes management and on prevention will also be most welcome. All applications will be considered on an equal basis and judged on their intrinsic scientific merit.

Funding

Up to Euro 2.1 million have been made available over 3 years for research in the framework of the Programme and performed in Europe and its associated countries. The awards will be distributed as follows:

2004 – 7 grants, each of Euro 100,000

2005 – 7 grants, “up to” Euro 100,000

2006 – 7 grants, “up to” Euro 100,000

Mechanisms of Support and Review

Research will be supported through the award of fixed grants, each of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000.

Applications for an EFSD/Novo Nordisk Research Programme Award are invited from single not-for-profit institutions or groups of affiliated institutions from Europe and associated countries. Applications will be subject to a scientific review by a specialised and independent ad hoc committee. Funding will require approval by a joint EFSD and Novo Nordisk Board convened for this purpose. It is anticipated that applications for the grant year 2005 will be received

by 1 December 2004 and approved for funding after review by March 2005.

Research Grant Applications

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review.

The deadlines for receipt of research grant applications for funding in 2005 is **1 December 2004**.

For the purpose of this programme, the budget of the research grants is limited to Euro 100,000 per annum. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification". EFSD and Novo Nordisk reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.

Application forms are available at:
foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not acceptable and will not be sent to reviewers.

Applications should be submitted by 1 December 2004 (date of receipt) to:

Viktor Jörgens, M.D., Executive Director
European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf, Germany

Review Considerations

Completed applications will be evaluated in accordance with the criteria stated below for scientific / technical merit by an appropriate scientific committee convened by EFSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem? If the aims of the application are achieved, how will scientific knowledge be ad-

vanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?

- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on diabetes mellitus.

Reporting Requirements

All Investigators funded by this Programme are required to submit a scientific report at the end of the funding period. Investigators must provide EFSD with early notice of papers accepted for publication and must acknowledge the support of the Programme in such papers by use of the phrase: "This work was made possible by an EFSD / Novo Nordisk Research Grant".

Competitive Renewal

Applications for renewal of a Research Programme Award will be accepted on a competitive basis, with the same review process as described in this announcement. Such applications will thus be considered in the same fashion as all other new applications received for review and without any special priority.

Schedule

Announcement:	September 2004 issue of <i>Diabetologia</i>
Application Deadline:	1 December 2004
Anticipated Award:	March 2005

Report on an EFSD/MSD Travel Fellowship for Young Scientists 2003

Christian Wrede

Department of Internal Medicine I, University of Regensburg, Germany

This is a short report on my two week stay at the laboratory of Prof. Philippe Halban, Centre Médical Universitaire, Geneva, Switzerland.

The inhibition of the NF kappa B signal transduction pathway by sodium salicylate has been shown to increase the activation of the insulin signaling cascade in liver and muscle tissue, thereby alleviating insulin resistance in Type 2 Diabetes mellitus. However, the effect of salicylates on pancreatic beta cells is less clear. My laboratory currently investigates the role of salicylates on NF kappa B activation and the possible crosstalk with mitogenic and antiapoptotic pathways

like IGF-1, MAPK, and PKB/Akt in pancreatic beta cells. Currently, we use the pancreatic tumour beta cell line INS-1 for experiments on beta cell mitogenesis and apoptosis. Although tumour cell lines are beneficial as a model, fluorescence activated cell sorted rat islet beta cells would offer the opportunity to confirm experimental data in primary cells without the possible interaction of surrounding alpha and delta cells.

The EFSD/MSD Travel Fellowship enabled me to stay two weeks at the laboratory of Prof. Philippe Halban in Geneva, Switzerland, to learn the methods of islet isolation and FAC-sorting of rodent beta cells. During this time, I had the opportunity to perform several rat islet isolations by collagenase digestion and histopaque gradient centrifugation, followed by islet trypsinization and autofluorescence FAC-sorting. This valuable training was essential to transfer these methods to my laboratory. In addition, I got the chance for scientific discussion of current projects of our groups, thereby providing the possibility to set up a collaboration.

I should like to take this opportunity to thank Prof. Halban and the members of his group very much for having me in their laboratory, for providing the training, for the scientific discussions and last but not least for giving me a warm welcome in Geneva. I also thank EFSD for its support in awarding me a Travel Fellowship.

Announcements

40th Annual Meeting of the EASD European Diabetes Epidemiology Group (EDEG)

Siofok, Hungary, 2–5 April 2005

The purpose of the meeting is to update researchers and clinicians on recent results in diabetes epidemiology.

The main topics will include:

- Usefulness of labels which identify hyperglycemic status.
- Diabetes prevention: the balance between social and individual process
- Novel and traditional risk factors for macro- and microvascular complications.
- Miscellaneous

For further information and announcements (abstract deadline etc.) please visit the EASD/EDEG website (www.easd.org) or contact:

Peter Stella
National Centre for Diabetes Care, 4th Dept. of Meds.
Tetenyi ut 12-16
H-1115 Budapest
Hungary
E-mail: stelp@vnet.hu
Tel/Fax: +36-1-464-8715

8th Annual Meeting of the Neuroendocrinology Section of the German Society of Endocrinology (DGE)

Berlin, Germany, 8–9 October, 2004

For more information:
<http://www.endokrinologie.net/neuroendokrinologie>

Fourth Genoa Meeting on Hypertension, Diabetes and Renal Diseases

Magazzini del Cotone, Genoa, Italy,
24–26 February 2005

Major Topics

- Social and economic issues in CV and renal prevention
- Development in antithrombotic treatment for high risk patients
- Lipids and renal disease
- New pharmacologic strategies for RAAS blockade
- Endothelial dysfunction as a marker of risk and a therapeutic target
- Insulin resistance and cardiovascular disease

- Cardiovascular abnormalities in patients with mild or moderate renal dysfunction
- Nutrition in diabetic chronic kidney disease
- Emerging cardiovascular risk factors in hypertension and diabetes
- Sympathetic nervous system activity in CRF
- Update in pancreas and kidney transplantation for treatment of diabetic nephropathy

The congress page is available on the web at the following address:

<http://www.aristea.com/diredi2005>

Third International Symposium on PPARs EFFICACY AND SAFETY FROM BASIC SCIENCE TO CLINICAL APPLICATIONS

Monte Carlo, Monaco, 19–23 March 2005

Co-chairpersons:

J.-C. Fruchart (France), R. Paoletti (Italy), J. Plutzky (USA), W. Wahli (Switzerland)

Scientific Secretaries:

A.L. Catapano (Italy), M. Crestani (Italy), B. Staels (France)

The abstract (oral and poster presentations) deadline is **7 December 2004**.

The abstract must be sent to the Scientific Organising Secretariat:

PPARs 2005

Fondazione Giovanni Lorenzini
Via Appiani, 7
I-20121 Milan
Italy
Tel.: + 39 (02) 29006267
Fax: + 39 (02) 29007018
E-mail: ppars@lorenzinifoundation.org

1st International Congress on 'Prediabetes' and Metabolic Syndrome Epidemiology, Management and Prevention of Diabetes and Cardiovascular Disease

Berlin, Germany, 13–17 April 2005

Main Topics:

- Definition and epidemiology of "Prediabetes" (IFG, IGT) and the Metabolic Syndrome
- Mechanisms leading to diabetes and cardiovascular disease (CVD)
- Dysglycemia as part of the metabolic syndrome: the pivotal role of obesity

- Screening strategies for “Prediabetes”: who should be screened and how?
- Interventions to prevent development of diabetes: lifestyle changes and pharmacotherapy
- Interventions to prevent CVD in “Prediabetes”: lifestyle changes and pharmacotherapy
- Managing dysglycemia in acute disease states
- Recommendations and guidelines for Health Authorities and individuals

Honorary Chair:

Pierre Lefèbvre, Belgium

Co-Chairs:

Sir George Alberti, UK

Avraham Karasik, Israel

Pesach Segal, Israel

Paul Zimmet, AO, Australia

Congress Organiser:

Kenes International

Global Congress Organizers

and Association Management Services

17 Rue du Cendrier

PO Box 1726

CH-1211 Geneva 1

Switzerland

Tel: +41 22 908 0488

Fax: +41 22 732 2850

E-mail: prediabetes@kenes.com

Website: <http://www.kenes.com/prediabetes>

Diabetes Technology Meeting

Pennsylvania Convention Center, Philadelphia,

28–30 October 2004

For more information:

www.diabetestechology.org

EASD News Section 9/2004

DOI 10.1007/s00125-004-1492-6